L'étude de l'apport en société des créations intellectuelles permet de dynamiser le schéma contractuel classique de la propriété intellectuelle reposant sur le couple cession-licence et contribue à l'analyse du mécanisme de l'apport en société. Malgré une similitude certaine avec les contrats usuels d'exploitation des biens intellectuels, l'apport des créations intellectuelles en société est une convention originale. Cette originalité se traduit par une nature et un régime hybrides. Du point de vue du droit de la propriété intellectuelle, il s'agit d'un contrat particulier d'exploitation des biens intellectuels. Du point de vue du droit de sociétés, il s'agit du contrat qui permet de mettre les biens intellectuels à la disposition de la société et de l'un des éléments constitutifs de celle-ci. Cette dualité a une incidence directe tant sur les conditions de réalisation de l'apport en société des créations intellectuelles que sur les effets de l'apport. Si le régime applicable s'appuie sur celui des contrats classiques d'exploitation des biens intellectuels, à savoir sur les règles prévues par le droit civil pour le contrat de vente et de louage des choses, il n'y a pourtant pas assimilation. D'une part, la réalisation de la convention d'apport obéit à de nombreuses contraintes dont celles résultant du droit des sociétés et du droit de la concurrence. D'autre part, l'appréhension des droits et des obligations des parties est différente. La relation entre la société et l'apporteur est imprégnée de l'intuitu personae inhérente aux biens intellectuels et de l'affectio societatis dû à la nature du contrat de société. En l'absence d'une règlementation adaptée à la spécificité du contrat, la liberté contractuelle s'exerce dans le respect des principes d'ordre public. / The study of the contribution agreement dynamizes the classic contractual scheme of intellectual property exploitation based on the pair licence- assignment and provides a detailed analysis of the mechanism of the contribution to a company. Despite a certain similarity to conventional intellectual property exploitation contracts, the contribution agreement is an original contract. This originality is reflected legally by a hybrid nature as well as a heterogeneous applicable system. Regarding intellectual property, the contribution agreement is a specific act of exploitation of intellectual goods. Regarding company law, it is the agreement which enables delivery of the intellectual goods to the company and constitutes an essential element of the company¿s constitution. This duality directly affects the conditions of contract formation as well as its effects. Although the applicable system is based on the traditional contracts of exploitation of intellectual goods, in particular the articles of civil law relating the sale and lease of tangible assets, there is no further similarity. On the one hand, the formation of the contribution agreement follows numerous constraints posed by company law and competition law. On the other hand, the understanding of the parties¿ rights and obligations differs. The relationship between the company and the contributor is imbued with the intuitu personae attached to intellectual goods as well as the affectio societatis resulting from the nature of the partnership agreement. Given the lack of regulation adapted to the specificity of intellectual property contribution agreements, the emphasis has been put on contract drafting. Such a legal deficiency must be supplemented by contractual freedom without breaking the principles of public policy.

La recherche dans le domaine des maladies sans traitement existant obéit à plusieurs impératifs définis par le législateur européen dans le règlement (CE) n° 141/2000 du 16 décembre 1999 concernant les médicaments orphelins. Les patients atteints de maladies rares et négligées ont le droit à « la même qualité de traitement que les autres » ce qui suppose de prendre les mesures d'incitation nécessaires pour « promouvoir la recherche, le développement et la commercialisation de traitements adéquats ». C'est un « domaine prioritaire ». Après avoir désigné les médicaments concernés, l'Union européenne veut « éviter la dispersion de ressources limitées » notamment par la promotion d'une « coopération transnationale ». Dans une démarche téléologique, cette recherche décrit les effets de la législation européenne sans ignorer la réception de ce droit par les États membres. Des fondements théoriques à même d'assurer une meilleure performativité du droit et des propositions concrètes en vue de conformer le droit positif à l'intention du législateur et aux attentes des parties prenantes sont proposés. En se focalisant sur le seul levier de la propriété intellectuelle, ce droit spécial et incitatif ne semble pas en mesure d'apporter aux patients la plupart des traitements attendus. La régulation de la concurrence et la compétence nationale sur le prix des médicaments perpétuent un seuil de rentabilité éloignant de nombreuses recherches de la phase du développement. L'accès aux médicaments orphelins demeure très restreint. Un changement de paradigme dans la construction de ce droit apparaît nécessaire afin qu'un modèle économique favorable se mette en place. Il convient que le profit des pharmaciens de l'industrie ne dépende plus de la conquête de parts de marché, mais de l'intérêt de leurs inventions pour les besoins de santé non satisfaits. / Research in the field of diseases without an existing treatment is governed by several requirements defined by the European legislator in Regulation (CE) No 141/2000 of 16 December 1999 on orphan medicinal products. Patients with rare and neglected diseases have the right to "the same quality of treatment as other patients" which means taking the necessary incentives to stimulate research, development and bringing to the market of appropriate medications". It is a "priority area". After designating the drugs concerned, the European Union wants to "avoid the dispersion of limited resources", in particular by promoting "cross national co-operation". In a teleological approach, this research analyses the positive law endeavouring to implement the objectives of Orphan Drug Law. It describes the effects of European legislation without ignoring the receipt of this law by the Member States. Theoretical foundations that can ensure a better performativity of the law, as well as concrete proposals to conform the positive law to the intention of the legislator and to the stakeholders' wills are proposed. By focusing solely on the leverage of intellectual property rights, this special and incentive law does not seem to be able to provide patients with many of the expected treatments. Competition regulation and setting of the price which is a national competency perpetuate a high profitability threshold, often withholding research projects from reaching the development phase. Access to orphan drugs remains very limited. A paradigm shift in the construction of this law appears necessary in order for a favorable economic model to emerge. The profit of the industry's pharmacists should no longer depend on the conquest of market shares, but on the value of their inventions for unmet health needs.

This master thesis is dedicated to the press publishers’ right introduced by Article 15 of the Directive (EU) 2019/790 on copyright and related rights in the Digital Single Market. The article became one of the most debated provisions in the whole directive. On the one hand, the discussion was driven by EU press publishers because of thecommercial crisis in the traditional press publishing and news mediasectors. Press representatives began to express concerns about the free riding of press publications by content aggregators and search engines who usually reuse such contents for profit. On the other hand, service providers argued that press publishers would lose traffic to their websites, affecting the quality of the press and constrainingfundamental rights. This conflict pushed the press publishers to bringing these issues before courts, legislators and competition authorities. Since these complaints were not resolved completely, the only way to resolve the conflict seemed to be the introduction of the EU-wide related right.

No description available.

The sui generis-right in article 7.1 of the database directive provides the maker of a database, who has made a qualitatively and/or quantitative substantial investment in the obtaining, verification and/or presentation of the contents in a database, the right to prevent extraction and/or re-utilization of the whole or of a substantial part of the database contents. In order to prevent the circumvention of article 7.1, the right to prohibit tortious dispositions of the contents was sup- plemented by article 7.5, which extends the right for the maker to prevent non-substantial parts to be extracted and/or re-utilized, provided that the extraction and/or re-utilization are repeated and systematic in a way that undermines the substantial investment the maker of the database has made.  The way that the sui generis-right is framed as an investment protection, in combination with the fact that the right’s object of protection is the investment as such, is the reason that the right has come to be regarded as a protection clause against unfair competition rather than an intellectual property right. As a result, the sui generis-right is of great significance to unfair competition and competition and antitrust law in general. This applies not only to article 102 FEUF, but especially to the DMA and in relation to the prescribed data-sharing obligation in article 6.10 in the DMA.  Competition and antitrust law in general and the DMA in particular, through its rootedness in article 3 FEU, aim to maintain competitive, open and fair digital markets. This applies, to say the least, as a part of ensuring the efficiency in the EU internal market, which by enlarge is intended to benefit the consumers. In this way, it’s understood that the consumers perspective plays a fundamental role in competition policy. In relation to the DMA, this is expressed through articles 6.2 and 6.10 of the DMA, which have the function of promoting innovation and increasing the consumers’ diversity of choice, while simultaneously giving the business users better opportunities to compete with the gatekeepers and thus become more efficient.  By imposing on a gatekeeper a far-reaching data-sharing obligation under article 6.10 in the DMA, in combination with the prohibition to use the same data under article 6.2, the gatekeepers’ sui generis-right is limited in all material aspects. Thereby, these provisions impose greatly on the gatekeepers’ ability as a maker of a database to freely dispose of their own database contents and thus obtain future returns and other competitive advantages as a result of the substantial investment. This is due to the fact that the gatekeeper is subject to an obligation to share the results of the investment with the business users.  The database directive states, however, that the sui generis-right must not be afforded in such a way as to facilitate abuses of a dominant position. By this reference it’s understood that this exception was written with article 102 FEUF in mind. In light of the significant differences between article 102 FEUF and the DMA, it can be concluded that the exception does not apply to the DMA. This is particularly the case as the DMA is framed as an ex ante-regulation, whereas article 102 FEUF is an ex post-regulation.  As this paper has highlighted, it requires great forethought when imposing a compulsory data-sharing obligation such as the one in article 6.10 in the DMA. The intended function of the sui generis-right is to promote investments in data processing and storage functions. In order to even receive or make use of the effective and high-quality data the business users have a right to receive from the gatekeepers, they have to have effective and proper databases, because otherwise it's entirely pointless to even force the gatekeepers to share their data.  Thus, a proportional balance is required between the interest in protecting the data as such by maintaining ex ante incentives to invest and the interest to promote open and fair digital markets as a way to ensure the effectiveness of the internal market for the benefit of the consumers and ex post social welfare. This could be a possible explanation to the Commission’s proposal of the Data Act, specifically article 35, which stipulates that the sui generis-right shall not be applied to machine generated data. It remains, however, to see how the question of the sui generis-right’s to be or not to be will play out in the future.

No description available.

Объектом исследования является идея осуществления производства антикоррозийных продуктов. Целью работы является обоснование экономической целесообразности реализации проекта по производству антикоррозийных продуктов. В процессе выполнения работы были получены следующие результаты. В рамках изучения методических подходов к оценке экономических перспектив были даны определения экономического и маркетингового анализа, определены их основные методы и задачи. А также составлена авторская классификация антикоррозионных продуктов, учитывающая их ключевые признаки. Результаты анализа рыночных и перспектив позволили выявить основных потребителей и конкурентов интересующего отраслевого рынка, а также позволили определить оптимальный объем выпуска антикоррозийного продукта и его среднерыночную стоимость. Таким образом, оптимальный объем выпуска, не нарушающий сложившегося рыночного равновесия, составляет порядка 30 тонн, а среднерыночная стоимость 1 тонны продукта составляет 100-110 тыс. рублей. Результаты патентного исследования, проведенного в рамках оценки научно-технических перспектив, позволили определить динамику патентования и выявить аналогичные технические решения. На основе результатов проведенного патентного исследования пределен средний срок жизни проекта по производству железооксидного пигмента с противокоррозионными свойствами – 4 года. Научно-практическим результатом, полученным автором в процессе выполнения работы, является создание модели производства, учитывающей более эффективные инструменты реализации идеи по производству антикоррозийных продуктов. В рамках этой модели, с учетом выводов, сделанных в аналитической части работы, рассчитаны показатели экономической эффективности трех вариантов трансфера технологии. / The object of the study is the idea of the production of anti-corrosion products. The purpose of the work is to justify the economic feasibility of the project for the production of anti-corrosion products. The following results were obtained in the course of the work. As part of the study of methodological approaches to the assessment of economic prospects, the definitions of economic and marketing analysis were given, their main methods and tasks were determined. And also the author's classification of anticorrosion products, taking into account their key features. The results of market and prospects analysis allowed to identify the main consumers and competitors of the industry market of interest, as well as to determine the optimal volume of production of anti-corrosion product and its average market value. Thus, the optimal volume of output that does not violate the existing market balance is about 30 tons, and the average market value of 1 ton of product is 100-110 thousand rubles. The results of the patent research conducted in the framework of the assessment of scientific and technical prospects allowed to determine the dynamics of patenting and to identify similar technical solutions. Based on the results of the patent research, the average life of the project for the production of iron oxide pigment with anti – corrosive properties is limited to 4 years. The scientific and practical result obtained by the author in the process of the work is the creation of a production model that takes into account more effective tools for the implementation of the idea for the production of anti-corrosion products. Within the framework of this model, taking into account the conclusions made in the analytical part of the work, the indicators of economic efficiency of the three options for technology transfer are calculated.

CubeSat missions needs components that are tolerant against the radiation in space. The hardware components must be reliable, and it must not compromise the functionality on-board during the mission. At the same time, the cost of hardware and its development should not be high. Hence, this thesis discusses the design and development of a CubeSat architecture using a Commercial Off-The- Shelf (COTS) Multi-Processor System on Chip (MPSoC). The architecture employs an affordable Rad-Hard Micro-Controller Unit as a Supervisor for the MPSoC. Also, it uses several radiation mitigation techniques such as the Latch-up protection circuit to protect it against Single-Event Latch-ups (SELs), Readback scrubbing for Non- Volatile Memories (NVMs) such as NOR Flash and Configuration scrubbing for the FPGA present in the MPSoC to protect it against Single-Event Upset (SEU)s, reliable communication using Cyclic Redundancy Check (CRC) and Space packet protocol. Apart from such functionalities, the Supervisor executes tasks such as Watchdog that monitors the liveliness of the applications running in the MPSoC, data logging, performing Over-The-Air Software/Firmware update. The thesis work implements functionalities such as Communication, Readback memory scrubbing, Configuration scrubbing using SEM-IP, Watchdog, and Software/Firmware update. The execution times of the functionalities are presented for the application done in the Supervisor. As for the Configuration scrubbing that was implemented in Programmable Logic (PL)/FPGA, results of area and latency are reported. / CubeSat-uppdrag behöver komponenter som är toleranta mot strålningen i rymden. Maskinvarukomponenterna måste vara pålitliga och funktionaliteten ombord får inte äventyras under uppdraget. Samtidigt bör kostnaden för hårdvara och dess utveckling inte vara hög. Därför diskuterar denna avhandling design och utveckling av en CubeSatarkitektur med hjälp av COTS (eng. Custom-off-The-Shelf) MPSoC (eng. Multi Processor System-on-Chip). Arkitekturen använder en prisvärd strålningshärdad (eng. Rad-Hard) Micro-Controller Unit(MCU) som Övervakare för MPSoC:en och använder också flera tekniker för att begränsa strålningens effekter såsom kretser för att skydda kretsen från s.k. Single Event Latch-Ups (SELs), återläsningsskrubbning för icke-volatila minnen (eng. Non-Volatile Memories) NVMs som NOR Flash och skrubbning av konfigurationsminnet skrubbning för FPGA:er i MPSoC:en för att skydda dem mot Single-Event Upsets (SEUs), och tillhandahålla pålitlig kommunikation mha CRC och Space Packet Protocol. Bortsett från sådana funktioner utför Övervakaren uppgifter som Watchdog för att övervaka att applikationerna som körs i MPSoC:en fortfarande är vid liv, dataloggning, och Over- the-Air-uppdateringar av programvaran/Firmware. Examensarbetet implementerar funktioner såsom kommunikation, återläsningsskrubbning av minnet, konfigurationsminnesskrubbning mha SEM- IP, Watchdog och uppdatering av programvara/firmware. Exekveringstiderna för utförandet av funktionerna presenteras för den applikationen som körs i Övervakaren. När det gäller konfigurationsminnesskrubbningen som implementerats i den programmerbara logiken i FPGA:n, rapporteras area och latens.

No description available.

No description available.